Physician profile
Ayad E Abrou
NPI 1457305815
$2,896.04
in general payments reported to CMS, 2019-2025
29 companies · $609 in 2025
The $609 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $150 · 2021: $260 · 2022: $258 · 2023: $532 · 2024: $889 · 2025: $609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,804 · Education: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,804.36 |
| Education | $226.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $390.54 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $277.45 | 2021-2025 | Sotyktu |
| Janssen Biotech, INC. | $227.16 | 2022-2025 | Tremfya, Remicade, Simponi |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $202.45 | 2019-2023 | Duobrii |
| Novartis Pharmaceuticals Corporation | $183.01 | 2022-2025 | |
| Genzyme Corporation | $181.37 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $169.49 | 2021-2025 | |
| Pfizer INC. | $146.45 | 2019-2025 | |
| Incyte Corporation | $112.32 | 2021-2024 | Opzelura |
| Galderma Laboratories, L.P. | $94.60 | 2021-2025 | Nemluvio, Aklief |
| Regeneron Healthcare Solutions, INC. | $92.10 | 2020-2024 | Libtayo, Dupixent |
| Dermavant Sciences, INC. | $83.38 | 2023-2024 | Vtama |
| Novo Nordisk INC | $82.56 | 2025 | Ozempic |
| Genentech USA, INC. | $79.86 | 2019-2022 | |
| Ucb, INC. | $75.90 | 2023-2025 | Bimzelx, Cimzia |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $69.96 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Kerecis Limited | $59.42 | 2023-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Amgen INC. | $54.10 | 2022-2025 | Otezla, Otezla |
| Allergan, INC. | $50.06 | 2020-2021 | |
| Organon LLC | $46.76 | 2025 | Vtama |
| Leo Pharma INC. | $34.27 | 2021-2024 | Adbry |
| Arcutis Biotherapeutics, INC. | $31.10 | 2023-2024 | Zoryve |
| Almirall LLC | $30.00 | 2024 | Klisyri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.60 | 2024 | Spevigo |
| Journey Medical Corporation | $22.91 | 2025 | |
| Organogenesis INC. | $20.56 | 2020 | |
| Celgene Corporation | $19.66 | 2019 | |
| Mayne Pharma Commercial LLC | $15.79 | 2022 | |
| Epi Health, LLC | $14.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayad Abrou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.